Chahra Khaoua Epouse Louafi
Chairman bei INSERM Transfert Initiative SAS
Profil
Chahra Khaoua Epouse Louafi is currently the Chairman-Supervisory Board at INSERM Transfert Initiative SAS.
She is also an Investment Director at BPIFrance Investissement SAS, a Director at Eyevensys SAS, a Director at MedDay Pharmaceuticals SAS, a Director at Therachon SAS, a Director at In Situ Training SAS, a Director at Brainever SAS, a Director at Incepto Medical SAS, a Director at Doctoconsult SAS, a Director at VectivBio AG, and a Fund Manager at Innobio 1 FCPI.
Additionally, she serves as a Member-Supervisory Board at Therachon Holding GmbH.
Ms. Louafi has previously worked as an Investment Director at CDC Enterprises, Inc. from 2001 to 2002.
She has also held positions as an Independent Director at DBV Technologies SA, a Director at Sensorion SA, a Director at Pixium Vision SA, a Director at Tissium SA, a Director at Annapurna Therapeutics SAS, an Executive Director at Lysogene SA, a Director at ENYO Pharma SA, a Director at Orphalan SA, a Director at SparingVision SAS, and an Independent Director at VectivBio Holding AG from 2019 to 2022.
Ms. Louafi has a graduate degree from Université Paris Dauphine-PSL, Institut National Agronomique Paris-Grignon, and Université Paris Nanterre.
Aktive Positionen von Chahra Khaoua Epouse Louafi
| Unternehmen | Position | Beginn |
|---|---|---|
BPIFrance Investissement SAS
 BPIFrance Investissement SAS Investment ManagersFinance BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development. | Private Equity Investor | 07.04.2010 |
Eyevensys SAS
 Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Director/Board Member | - |
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Director/Board Member | 08.04.2016 |
Brainever SAS
 Brainever SAS Pharmaceuticals: MajorHealth Technology Brainever SAS manufactures pharmaceutical products. It develops medicines for nervous system diseases. The company was founded on March 31, 2015 and is headquartered in Paris, France. | Director/Board Member | - |
In Situ Training SAS
 In Situ Training SAS Miscellaneous Commercial ServicesCommercial Services In Situ Training SAS provides medical training services. It specializes in e-medicine, Medical Training, In Situ Training, Digital Health, e-health and Training inside the OR. The company was founded by Patxi Ospital and Julien Delpech in 2015 and is headquartered in Pessac, France. | Director/Board Member | - |
Therachon SAS
 Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Director/Board Member | - |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Director/Board Member | - |
INSERM Transfert Initiative SAS
 INSERM Transfert Initiative SAS Investment ManagersFinance INSERM Transfert Initiative SAS is a venture capital fund that invests in companies located in France. It targets startups from the life sciences and biotechnology sectors, developing new medical practices with a strong intellectual property. It invests between €1 million and €3 million per company during mostly at pre-seed, seed and early-stages. | Chairman | - |
Incepto Medical SAS
 Incepto Medical SAS Packaged SoftwareTechnology Services Incepto Medical SAS develops and distributes artificial intelligent (AI) based medical imaging applications. It offers solutions for computed tomography (CT) scans, chest x-ray, and detections for conditions such as fracture and bowel occlusion. The company was founded by Antoine Jomier, Florence Moreau, Vincent Barrau, Jean Michel Malbrancq, and Gaspard d’Assignies and is headquartered in Paris, France. | Director/Board Member | - |
| ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Ehemalige bekannte Positionen von Chahra Khaoua Epouse Louafi
| Unternehmen | Position | Ende |
|---|---|---|
| ░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Ausbildung von Chahra Khaoua Epouse Louafi
| Université Paris Dauphine-PSL | Graduate Degree |
| Institut National Agronomique Paris-Grignon | Graduate Degree |
| Université Paris Nanterre | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| DBV TECHNOLOGIES | Health Technology |
| SENSORION | Health Technology |
| PIXIUM VISION | Health Technology |
| LYSOGENE | Commercial Services |
| Private Unternehmen | 19 |
|---|---|
CDC Enterprises, Inc.
 CDC Enterprises, Inc. Electrical ProductsProducer Manufacturing CDC Enterprises, Inc. designs, manufactures, and distributes patented HDPE ductwork products. It offers airtight, mildew, corrosion resistant, and thermal constructed ductwork products. The firm specializes in electrical instrumentation, controls and systems integration, for public works, utilities, private industry, and government organizations. It provides a wide range of services including pump efficiency monitoring, system diagnostics and troubleshooting, GPS mapping, robotic controls, panel design, and fabrication. The company was founded by Jon W. Jungers in April 2001 and is headquartered in Ringwood, IL. | Producer Manufacturing |
BPIFrance Investissement SAS
BPIFrance Investissement SAS Investment ManagersFinance BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development. | Finance |
INSERM Transfert Initiative SAS
INSERM Transfert Initiative SAS Investment ManagersFinance INSERM Transfert Initiative SAS is a venture capital fund that invests in companies located in France. It targets startups from the life sciences and biotechnology sectors, developing new medical practices with a strong intellectual property. It invests between €1 million and €3 million per company during mostly at pre-seed, seed and early-stages. | Finance |
Innobio 1 FCPI
 Innobio 1 FCPI Investment ManagersFinance Innobio FCPI seeks investment opportunities in companies located in France. The fund focuses on innovative technology products and services in the healthcare market. It provides financing for early stage capital requirements and can invest between EUR 3 and EUR 10 million per target. | Finance |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Commercial Services |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Health Technology |
Tissium SA
 Tissium SA BiotechnologyHealth Technology Tissium SA engages in the development and commercialization of biodegradable sealants and adhesives for invasive surgery. It offers biomimetic wound closure solutions. The company was founded by Bernard J. Gilly, Robert S. Langer, Christophe Bancel, Jeff Karp, Jacques Marescaux, Maria Pereira, and Patrick Houvet in 2013 and is headquartered in Paris, France. | Health Technology |
Annapurna Therapeutics SAS
 Annapurna Therapeutics SAS BiotechnologyHealth Technology Annapurna Therapeutics SAS operates as a gene therapy company. Its therapy restored cardiac function and reversed pathological heart enlargement in mice that had already progressed to heart failure. The company was founded by Pierre Bougneres, Hélène Puccio, Amber Salzman, Patrick Aubourg and Ronald G. Crystal and is headquartered in Paris, France. | Health Technology |
Therachon SAS
Therachon SAS BiotechnologyHealth Technology TherAchon SAS provides biotechnology services. It specializes in research and development for achondroplasia and its associated complications. The company was founded by Elvire Gouze in 2014 and is headquartered in Biot, France. | Health Technology |
ENYO Pharma SA
 ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Health Technology |
In Situ Training SAS
In Situ Training SAS Miscellaneous Commercial ServicesCommercial Services In Situ Training SAS provides medical training services. It specializes in e-medicine, Medical Training, In Situ Training, Digital Health, e-health and Training inside the OR. The company was founded by Patxi Ospital and Julien Delpech in 2015 and is headquartered in Pessac, France. | Commercial Services |
Brainever SAS
Brainever SAS Pharmaceuticals: MajorHealth Technology Brainever SAS manufactures pharmaceutical products. It develops medicines for nervous system diseases. The company was founded on March 31, 2015 and is headquartered in Paris, France. | Health Technology |
Orphalan SA
 Orphalan SA Pharmaceuticals: MajorHealth Technology GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France. | Health Technology |
SparingVision SAS
 SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Health Technology |
Therachon Holding GmbH
 Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland. | Health Technology |
Incepto Medical SAS
Incepto Medical SAS Packaged SoftwareTechnology Services Incepto Medical SAS develops and distributes artificial intelligent (AI) based medical imaging applications. It offers solutions for computed tomography (CT) scans, chest x-ray, and detections for conditions such as fracture and bowel occlusion. The company was founded by Antoine Jomier, Florence Moreau, Vincent Barrau, Jean Michel Malbrancq, and Gaspard d’Assignies and is headquartered in Paris, France. | Technology Services |
Doctoconsult SAS
 Doctoconsult SAS Internet Software/ServicesTechnology Services Doctoconsult SAS operates an online portal, which provides telemedecine services. It specializes in mental health. The company was founded by Grevent Fanny Jacq in 2016 and is headquartered in Fresnes, France. | Technology Services |
VectivBio Holding AG
 VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
